RadioMedix (225Ac-PSMA I&T Program) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

RadioMedix (225Ac-PSMA I&T Program) General Information

Description

225Ac-PSMA I&T Asset, a targeted alpha therapy (TAT) for metastatic castration-resistant prostate cancer program located in Houston, Texas.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Houston, TX
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Corporate Office
  • Houston, TX
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RadioMedix (225Ac-PSMA I&T Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RadioMedix (225Ac-PSMA I&T Program)‘s full profile, request access.

Request a free trial

RadioMedix (225Ac-PSMA I&T Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore RadioMedix (225Ac-PSMA I&T Program)‘s full profile, request access.

Request a free trial

RadioMedix (225Ac-PSMA I&T Program) FAQs

  • Where is RadioMedix (225Ac-PSMA I&T Program) headquartered?

    RadioMedix (225Ac-PSMA I&T Program) is headquartered in Houston, TX.

  • What industry is RadioMedix (225Ac-PSMA I&T Program) in?

    RadioMedix (225Ac-PSMA I&T Program)’s primary industry is Buildings and Property.

  • Is RadioMedix (225Ac-PSMA I&T Program) a private or public company?

    RadioMedix (225Ac-PSMA I&T Program) is a Private company.

  • What is RadioMedix (225Ac-PSMA I&T Program)’s current revenue?

    The current revenue for RadioMedix (225Ac-PSMA I&T Program) is .

  • Who are RadioMedix (225Ac-PSMA I&T Program)’s investors?

    RadioMedix has invested in RadioMedix (225Ac-PSMA I&T Program).

  • When was RadioMedix (225Ac-PSMA I&T Program) acquired?

    RadioMedix (225Ac-PSMA I&T Program) was acquired on 13-Feb-2023.

  • Who acquired RadioMedix (225Ac-PSMA I&T Program)?

    RadioMedix (225Ac-PSMA I&T Program) was acquired by Fusion Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process